Alpha 2.0
Login Register
» Authors » Mark S Shaefer

Mark S Shaefer

Explore the profile of Mark S Shaefer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 27
Citations 347
Followers 0
Related Specialties
Infectious Diseases
Pharmacology
General Medicine
Top 10 Co-Authors
Lisa L Ross
Edwin DeJesus
Benjamin Young
Henry H Zhao
Kathleen E Squires
Vani Vannappagari
Daniel Murphy
David A Margolis
Qiming Liao
Michael L Lim
Published In
Pharmacotherapy
HIV Clin Trials
AIDS
PLoS One
J Acquir Immune Defic Syndr
Affiliations
Soon will be listed here.
Recent Articles
11.
Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine
Young B, Squires K, Tashima K, Henry K, Schneider S, LaMarca A, et al.
HIV Clin Trials . 2015 Jul; 16(4):125-9. PMID: 26133089
No abstract available.
12.
Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial
Wohl D, Bhatti L, Small C, Edelstein H, Zhao H, Margolis D, et al.
PLoS One . 2014 May; 9(5):e96187. PMID: 24825167
Objective: Simplification of antiretroviral therapy in patients with suppressed viremia may minimize long-term adverse effects. The study's primary objective was to determine whether abacavir/lamivudine + atazanavir (ABC/3TC+ATV) was virologically non-inferior...
13.
HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencing
Ross L, Horton J, Hasan S, Brown J, Murphy D, DeJesus E, et al.
PLoS One . 2014 Mar; 9(2):e89611. PMID: 24586911
Factors that contribute to the transmission of human immunodeficiency virus type 1 (HIV-1), especially drug-resistant HIV-1 variants remain a significant public health concern. In-depth phylogenetic analyses of viral sequences obtained...
14.
ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine
Squires K, Young B, DeJesus E, Bellos N, Murphy D, Ward D, et al.
HIV Clin Trials . 2012 Nov; 13(5):233-44. PMID: 23134624
Background: The open-label study ARIES (ClinicalTrials.gov NCT00440947) utilized a ritonavir (/r)-boosted protease inhibitor treatment simplification strategy. Antiretroviral-naïve subjects received abacavir/lamivudine (ABC/3TC) + atazanavir/ ritonavir (ATV/r) from baseline through randomization at...
15.
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES
Young B, Squires K, Ross L, Santiago L, Sloan L, Zhao H, et al.
AIDS Res Hum Retroviruses . 2012 Oct; 29(2):350-8. PMID: 23039030
Propensity for developing coronary heart disease (CHD) is linked with Framingham-defined cardiovascular risk factors and elevated inflammatory biomarkers. Cardiovascular risk and inflammatory biomarkers were evaluated in ARIES, a Phase IIIb/IV...
16.
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients
Squires K, Young B, DeJesus E, Bellos N, Murphy D, Zhao H, et al.
AIDS . 2010 Jul; 24(13):2019-27. PMID: 20613461
Background: Treatment simplification strategies involving induction with a ritonavir (RTV)-boosted (/r) protease inhibitor regimen followed by simplification (without RTV) are appealing because they may offer sustained virologic suppression while minimizing...
17.
Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients
Squires K, Young B, DeJesus E, Bellos N, Murphy D, Sutherland-Phillips D, et al.
HIV Clin Trials . 2010 Jun; 11(2):69-79. PMID: 20542844
Purpose: The ARIES study assessed safety and efficacy of an induction regimen with atazanavir/ritonavir (ATV/RTV) + abacavir/lamivudine (ABC/3TC) followed by simplification to ATV + ABC/3TC in antiretroviral-naïve patients. Methods: This...
18.
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment
Smith K, Patel P, Fine D, Bellos N, Sloan L, Lackey P, et al.
AIDS . 2009 Jun; 23(12):1547-56. PMID: 19542866
Background: Abacavir sulfate/lamivudine (ABC/3TC) and tenofovir DF/emtricitabine (TDF/FTC) are widely used nucleoside reverse transcriptase inhibitors for initial HIV-1 treatment. This is the first completed, randomized clinical trial to directly compare...
19.
A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION...
Kumar P, Salvato P, LaMarca A, DeJesus E, Patel P, Mcclernon D, et al.
AIDS Res Ther . 2009 Apr; 6:3. PMID: 19358725
Background: Traditional first line regimens containing a non-nucleoside reverse transcriptase inhibitor or protease inhibitor may not be suitable for a subset of antiretroviral-naïve patients such as those with certain co-morbidities,...
20.
Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study
Cohen C, Kubota M, Brachman P, Harley W, Schneider S, Williams V, et al.
Pharmacotherapy . 2008 Feb; 28(3):314-22. PMID: 18294111
Study Objective: To evaluate the short-term (12 wks) safety and tolerability of a once-daily, fixed-dose abacavir-lamivudine combination versus twice-daily dosing of the separate components, both with background antiretroviral therapy. Design:...